New Treatment Approaches on the Horizon for Patients With HAE Three therapies—berotralstat, sebetralstat, and lonvo-z—could offer hope to those who suffer from HAE attacks, which can be life-threatening.

Three therapies—#Berotralstat, #Sebetralstat, and #LonvoZ—could offer hope to those who suffer from #HAE attacks, which can be life-threatening.

Read the full feature here: https://bit.ly/3LJb9WX

#RareDisease #HereditaryAngioedema

Single-Dose CRISPR Therapy Shows Durable HAE Control A single dose of lonvo-z kept nearly all patients with HAE attack-free and off prophylaxis for months to years.

A single dose of #LonvoZ, @intelliatx.bsky.social #CRISPR therapy for #HAE, produced deep, long-lasting suppression of #Kallikrein and kept nearly all patients attack-free and off prophylaxis for months to years, with a strong safety profile.

Read here: https://bit.ly/48vZ5zN

#RareDisease #MedSky

One-Time Infusion of Lonvo-Z May Safely Prevent Attacks in HAE Adverse events were common but were mostly mild to moderate reactions that resolved rapidly.

#ACAAI25: A single 50-mg infusion of lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (#HAE) appears to offer high rates of attack-free and long-term prophylaxis (#LTP)-free status.

Read here: https://bit.ly/3JCy3yg

#RareDisease #HereditaryAngioedema #LonvoZ #MedSky

#HAE #GeneTherapy #CRISPR #LonvoZ #ClinicalTrial #RareDisease #ChronicIllness #PatientAdvocacy #MedicalInnovation #AngioedemaAwareness #HopeForHAE #SpoonieCommunity #AutoimmuneSupport #HealthBreakthrough #BioNews #AngioedemaNews